NECFA
ORKA

New England Capital Financial Advisors’s Oruka Therapeutics ORKA Stock Holding History

New England Capital Financial Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-41
Closed -$1K – 423
2024
Q3 		$1K Buy
+41
New +$1.43K ﹤0.01% 343

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

New England Capital Financial Advisors's ORKA Position: Q4 2024 in Review

New England Capital Financial Advisors sold out of Oruka Therapeutics (ORKA) in Q4 2024, closing a stake of 41 shares — an estimated $1K sold.

New England Capital Financial Advisors first reported a position in ORKA in Q3 2024 and held it in 1 quarter. The position peaked at $1K in Q3 2024. 66 funds tracked by Wall St. Rank hold ORKA as of Q4 2024.

  • New England Capital Financial Advisors reported no remaining Oruka Therapeutics position as of Q4 2024 after selling out during the quarter.
  • New England Capital Financial Advisors sold 41 Oruka Therapeutics shares in Q4 2024, an estimated $1K.
  • New England Capital Financial Advisors first reported a position in Oruka Therapeutics in Q3 2024 and held it in 1 quarter.
  • New England Capital Financial Advisors's Oruka Therapeutics position peaked at $1K in Q3 2024.
  • 66 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q4 2024.

Based on New England Capital Financial Advisors's 13F filing for Q4 2024, filed 4 Feb 2025.